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Objectives:  Epidermal  growth  factor  receptor  (EGFR)  mutation  testing  is  standard  practice  after  lung  ade-
nocarcinoma  diagnosis,  and  provision  of  high-quality  tumor  tissue  is  ideal.  However,  there  are  knowledge
gaps  regarding  the  utility  of  cytology  or low  tumor  content  histology  samples  to  establish  EGFR  mutation
status,  particularly  with  regard  to the  proportion  of  testing  performed  using  these  sample  types,  and  the
lack  of  an  established  link  with  efﬁcacy  of treatment.
Methods: The  randomized  phase  III Iressa  Pan-ASia  Study  (IPASS;  ClinicalTrials.gov  identiﬁer
NCT00322452)  of  ﬁrst-line  geﬁtinib  versus  chemotherapy  analyzed  samples  meeting  preplanned  speci-
ﬁcations  (n =  437  evaluable  for  EGFR  mutation;  n  =  261  mutation-positive).  This  supplementary  analysis
assessed  tumor  content  and  mutation  status  of  histology  (n  =  99)  and  cytology  samples  (n  = 116)  which
were  previously  unanalyzed  due  to  sample  quality,  type,  and  tumor  content  (<100  cells).  Objective
response  rate  (ORR)  and  change  in  tumor  size  with  geﬁtinib  treatment  were  assessed.
Results: EGFR  mutation  testing  was  successful  in  80%  and  19%  of  previously  unanalyzed  histology  and
cytology  samples,  respectively.  Mutations  were  detected  in 54  tumors  previously  described  as  mutation-
unknown  (histology,  n  =  45;  cytology,  n =  9).  ORRs  in mutation-positive  cytology  (83%)  and  histology  (74%)
subgroups  were  consistent  with  previous  analyses  (71%).  Tumor  size  decrease  was  consistent  across
previously  analyzed  and  unanalyzed  samples  (all  mutation  subgroups),  with  less  consistency  across  ORRs
in  mutation-negative  cytology  (16%)  and  histology  (25%)  subgroups  versus  the  previous  analysis  (1%).
Conclusions: Histology  samples  with  low  tumor  content  and  cytology  samples  can  be  used  for  EGFR
mutation  testing;  patients  whose  mutation  status  was  conﬁrmed  using  these  sample  types  achieved
a  response  to  treatment  consi
sample  quantity/quality  can  po
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1. Introduction
Non-small-cell lung cancer (NSCLC) is traditionally treated using
platinum-based chemotherapy [1,2]. Recently, the management of
advanced lung adenocarcinoma has evolved, and use of molecu-
lar diagnosis to investigate driver mutations in tumor samples has
Open access under CC BY-NC-ND license.become the most important step toward selecting the right agent
for a patient’s treatment [3].
The most established example is the use of epidermal growth
factor receptor (EGFR) mutations as a predictive marker of tumor
-NC-ND license.
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esponse to EGFR tyrosine kinase inhibitor (TKI) treatment. The
rst trial to conﬁrm the utility of EGFR mutation as a predic-
or of anticancer efﬁcacy was the Iressa Pan-ASia Study (IPASS),
hich investigated the outcomes of the overall study population
n = 1217) and subgroups (including those evaluable for EGFR muta-
ion status [n = 437]) treated with geﬁtinib or carboplatin/paclitaxel
4,5]. IPASS demonstrated superior progression-free survival (PFS),
bjective response rate (ORR), symptom control, and quality of
ife with ﬁrst-line geﬁtinib versus carboplatin/paclitaxel in patients
ith EGFR mutation-positive tumors. This ﬁnding was  replicated in
he smaller FIRST-Signal study [6]. Five additional phase III stud-
es have subsequently reported signiﬁcantly increased PFS with
GFR-TKIs (geﬁtinib, erlotinib, and afatinib) versus platinum-based
hemotherapy in patients with EGFR mutation-positive tumors
7–11].
IPASS (overall population n = 1217) included exploratory objec-
ives to investigate efﬁcacy according to EGFR biomarker status
EGFR mutation, gene copy number, and protein expression) [4,5].
ollection of histology samples for biomarker analysis was not
andated; 85% of patients consented to donate their tumor. Sam-
les were provided by 683/1217 patients (56%). Fukuoka et al.
resented the IPASS exploratory biomarker data for 261 patients
ith EGFR mutation-positive tumors out of 437 evaluable patients
60%) [4].
The  streamlined biomarker analysis process (Fig. 1) required all
amples to meet stringent pre-speciﬁed thresholds for the number
f tumor cells and sample quality/type, based on the higher
ell requirements of ﬂuorescent in situ hybridization (FISH) for
ene copy number and immunohistochemistry (IHC) for protein
xpression. Prior to EGFR mutation analysis samples underwent
entral histopathological review, and samples were included in
he biomarker analysis based on their quality, quantity, type, and
umor content (>100 cells) (Fig. 1). These criteria ensured quality
esults, reﬂecting the design of IPASS, determination of differential
fﬁcacy in biomarker positive/negative subgroups, limited data at
he time regarding the predictive nature of the biomarkers, and
xtent of validation of the biomarker assays at the time IPASS
as conducted (biomarker assays were not validated for cytology
Provision of sample
Assessment of
sample type Pathology review
No – define as ‘unknown’
a) Cytology – do not proceed
to pathology review. Define
as ‘unknown’
a) Fail (insu fficient quantity
and/or quality)  – do not
proceed. Define as ‘unknown’
Yes – proceed to assessment
of sample type
b) Tumor – p roceed to
pathology review
b) Pass (suitable quantity and
quality) – proceed to EGFR
mutation analysis
If 
p
Histology samples that failed pathology review due to insufficient tumor material for biomarker analysis (<100 tumor 
(inadequate fixation or a sample where accurate diagnosis was not possible) and we re therefo re not included in the m 
Previously unanalyzed samples included cytology samples and any samples that did not pass pathology review (high
EGFR, epidermal g rowth factor  receptor; IPASS, I ressa Pan-ASia Stud y.
Biomarker Analysis
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samples  at that time). This approach provided a deﬁnitive answer
regarding patients who derived most beneﬁt in the clinical setting.
While appropriate to answer the questions posed by the IPASS
protocol, the EGFR mutation analysis threshold stringency was
higher than would be employed for the diagnosis of patients in
daily practice. Since IPASS reported, laboratories have gained
experience of using existing EGFR mutation detection techniques
on a spectrum of samples with varying tumor content and sample
quality. Small biopsies and cytology samples make up ∼30–80% of
available diagnostic material, depending on diagnostic practices
between different hospitals and countries [12], therefore their
successful testing is paramount to ensure this sizeable propor-
tion of patients are given the opportunity to receive optimal
treatment. The percentage of mutation testing that occurs using
cytology samples can be very variable however, and is currently
not consistent across institutions or countries [13]. Smouse et al’s
retrospective review of EGFR sequencing over a two  year period
at a US hospital noted that only 12/239 (5%) specimens tested for
EGFR mutation were cytological in origin [13], with focus given
to the testing of high-quality tumor tissue samples. Conversely,
Hagiwara et al. recently noted that ∼40% of samples submitted for
EGFR mutation testing across three major commercial test centers
in Japan were of cytological origin [14], further commenting
that this high percentage highlights that cytological samples are
indispensable for testing all patients with advanced NSCLC.
The  aim of the current study was to investigate whether
cytology/histology samples that were not included in the IPASS pre-
planned exploratory biomarker analyses could be used successfully
to deﬁne EGFR mutation status and predict which patients were
more likely to respond to EGFR-TKI treatment. We describe data
generated from pathology review and mutation analysis of the pre-
viously unanalyzed histology samples and previously unanalyzed
cytology samples, with the aim of testing the outcome of patients
with NSCLC as per the study protocol, but by looking at the full spec-
trum of samples that are available from this population of patients.
These data will help to inform the most appropriate thresholds for
further trials, as well as the utility of samples received by diagnostic
laboratories on a daily basis.
1. Biomarker analysis I:
EGFR mutation analysis
2. Biomarker analysis II: EGFR
gene copy number analysis
3. Biomarker analysis III:
EGFR protein
expression analysis
Evaluable:
Postive / negative
Evaluable:
High / low
Evaluable:
High / low
Non-evaluable:
Define as ‘unknown’
Non-evaluable:
 Define as ‘unknown’
Non-evaluable:
 Define as ‘unknown’
sufficient sample  remaining,
roceed to EGFR gene copy
number analysis
If sufficient sample  remaining,
proceed to EGFR p rotein
expression analysis
If sufficient sample  remaining,
proceed to EGFR p rotein
expression analysis
cells) or poor quality
ain IPASS biomarker analyses.
lighted in red). 
 Procedu re
analysis process.
1 g Canc
2
2
h
i
c
b
i
y
n
P
s
p
i
s
e
E
i
e
ﬁ
a
r
(
t
a
p
t
a
n
i
[
p
a
t
t
a
2
o
I
o
l
b
l
t
t
s
p
i
2
t
h
T
(
c
v
c76 J.C.-H. Yang et al. / Lun
. Materials and methods
.1.  Study design and patients
Full  details of IPASS (ClinicalTrials.gov identiﬁer NCT00322452)
ave been published previously [4,5]. Patients were eligible for
nclusion into the study if they had histologically or cytologically
onﬁrmed stage IIIB or IV pulmonary adenocarcinoma (including
ronchoalveolar carcinoma), were never-smokers (<100 cigarettes
n their lifetime) or former light smokers (stopped smoking ≥15
ears previously and smoked ≤10 pack-years), and had received
o prior chemotherapy, biologic therapy, or immunologic therapy.
atients provided written informed consent with separate con-
ent for the optional assessment of EGFR biomarkers. The study
rotocol was approved by independent ethics committees at each
nstitution. Of 1217 randomized patients, 683 (56%) provided a
ample for biomarker analysis. Tumor EGFR mutation status was
valuable for 437 patients (261 EGFR mutation-positive). Prior to
GFR mutation analysis samples underwent central histopatholog-
cal review; only those considered suitable for the analysis of all
xploratory biomarkers, including two methods requiring a speci-
ed cell number (EGFR gene ampliﬁcation by FISH requiring 60 cells,
nd EGFR protein expression by IHC requiring 100 cells, for accu-
ate scoring respectively), were included in the biomarker analysis
sample quality, type, and tumor content [>100 cells]) (Fig. 1). At the
ime of the original analysis, according to the protocol biomarker
nalyses were not performed for 215 samples: 116 cytology sam-
les (biomarker analyses had not been validated for this sample
ype, as previously reported in the appendix of Fukuoka et al. [4])
nd 99 histology samples (determined during pathology review
ot to meet pre-speciﬁed biomarker analysis thresholds regard-
ng tumor content [>100 tumor cells] and sample quality/quantity
including samples with inadequate cellular morphology due to
oor/inappropriate ﬁxation]). The previously unanalyzed cytology
nd histology samples are the subject of this additional analysis.
The  study was conducted in accordance with the Declara-
ion of Helsinki, the International Conference on Harmonisa-
ion/Good Clinical Practice, applicable regulatory requirements,
nd AstraZeneca’s policy on bioethics.
.2. EGFR mutation analyses
EGFR  mutation analyses were conducted at two  central lab-
ratories (Genzyme, Framingham, MA,  USA and AstraZeneca
nnovation Center China, Shanghai, China). EGFR mutation status
f the previously unanalyzed samples was determined by ana-
yzing parafﬁn-embedded archival histological and cytological cell
locks/smears. Sample tumor content was assessed (histopatho-
ogical review) prior to categorization based on the number of
umor cells present; 0–9, 10–49, 50–99, and >100 cells. EGFR muta-
ions were detected using an ampliﬁcation mutation refractory
ystem with EGFR mutation detection (Qiagen, Manchester, UK), as
reviously reported for IPASS [5]. Tumors were considered positive
f ≥1 of 29 EGFR mutations was detected.
.3. Statistical analyses
Statistical  analyses were performed by AstraZeneca. Owing to
he small numbers of evaluable cytology and previously unanalyzed
istology samples, formal statistical testing was not appropriate.
he ORR with exact 95% (Clopper–Pearson) conﬁdence intervals
CIs) was calculated for EGFR mutation-positive and -negative
ytology samples and EGFR mutation-positive and -negative pre-
iously unanalyzed histology samples.
Percentage change in tumor size was presented graphi-
ally (waterfall plots), with each patient’s maximum percentageer 83 (2014) 174– 181
decrease  in tumor size presented as a separate bar (largest increase
to largest decrease).
3.  Results
3.1. Patients
A  total of 215 samples (99 histology; 116 cytology) were avail-
able but not analyzed in the main IPASS analysis (Fig. 2). Of the 99
histology samples, 79 (80%) were evaluable for EGFR mutations of
which 45 (57%) were EGFR mutation-positive. Of these 45 patients
with EGFR mutation-positive tumors, 27 (60%) had received geﬁ-
tinib and 18 (40%) carboplatin/paclitaxel. Of  the 116 cytology
samples, 31 (19%) were evaluable for EGFR mutation of which nine
(29%) were EGFR mutation-positive. Of these nine patients with
EGFR mutation-positive tumors, six (67%) had received geﬁtinib
and three (33%) carboplatin/paclitaxel. A total of 20 histology sam-
ples (20%) and 85 cytology samples (73%) were not evaluable for
EGFR mutation status (insufﬁcient DNA for mutation analysis or no
material available for DNA extraction and subsequent analysis).
3.2.  Analysis success and tumor cell number: cytology and
histology samples that previously failed pathology review
Fig.  3 summarizes the number of evaluable and EGFR mutation-
positive samples observed, according to tumor cell content. A total
of 52 cytology samples (45%) had <100 tumor cells; eleven of these
samples provided an evaluable EGFR mutation result, of which two
(18%) were EGFR mutation-positive. A total of 64 cytology samples
(55%) had >100 tumor cells; twenty of these samples provided an
evaluable EGFR mutation result, of which seven (35%) were EGFR
mutation-positive.
Data from the previously unanalyzed histology samples showed
that 73 samples (74%) had <100 tumor cells, with 59 samples pro-
viding an evaluable EGFR mutation result; thirty (51%) were EGFR
mutation-positive. A total of 26 histology samples (26%) had >100
tumor cells. These samples had previously been excluded from
the main IPASS study on the basis that they did not meet the
pre-speciﬁed thresholds regarding tumor content and sample qual-
ity/quantity (described in Section 2). Twenty samples provided an
evaluable EGFR mutation result; 15 (75%) were EGFR mutation-
positive.
In total, therefore, EGFR mutation-positive tumors were
detected in 54 patients which had previously been described as
EGFR mutation-unknown.
3.3.  Mutation subtype and frequency
Of the EGFR mutation-positive cytology samples, 5 (55.6%) were
positive for exon 19 deletions and 4 (44.4%) were positive for exon
21 L858R. Of the EGFR mutation-positive histology samples, 22
(48.9%) were positive for exon 19 deletions, 18 (40%) for exon 21
L858R, and two (4.4%) for exon 18 G719S/A/C. A total of three sam-
ples were identiﬁed as having double mutations: two (4.4%) for
exon 19 deletions and exon 21 L858R, and one sample (2.2%) for
exon 18 G719S/A/C and exon 21 L861Q.
3.4. Efﬁcacy
Data from the previously analyzed samples demonstrated the
differential efﬁcacy in terms of ORRs for patients with geﬁ-
tinib, with 1% of patients (n = 1/100) having an objective response
in the EGFR mutation-negative subgroup, 43% (n = 167/386) in
the mutation-unknown subgroup, and 71% (n = 94/132) in the
mutation-positive subgroup [4,5]. Note that in the previous anal-
ysis, the EGFR mutation-unknown subgroup consisted of 386
J.C.-H. Yang et al. / Lung Cancer 83 (2014) 174– 181 177
215 previously unanalyzed
samples
99 histology samples 116 cytology samples
45 mutation-positive
(27 had received gefitinib;
18 had received
carboplatin / paclitaxel)
9 mutation-positive
(6 had received gefitinib;
3 had received
carboplatin / paclitaxel)
34 mutation-negative
(16 had received gefitinib;
18 had received
carboplatin / paclitaxel)
22 mutation-negative
(12 had received gefitinib;
10 had received
carboplatin / paclitaxel)
20 unknown mutation status
(12 had received gefitinib;
8 had received
carboplatin / paclitaxel)
79 known mutation status
85 unknown mutation status
(44 had received gefitinib;
41 had received
carboplatin / paclitaxel)
31 known mutation status
Among the 105 patients for whom tumor EGFR mutation status was unknown, the main reasons for unknown EGFR mutation status were
insufficient DNA for analysis, no material available for analysis, inadequate fixation, and patient diagnosis unable to be confirmed.
EGFR, epidermal growth factor receptor. 
Fig. 2. Sample disposition.
Cytology
Sample type and no. of tumor cells per sample
EGFR mutations were identified in both the previously unanalyzed histology and cytology samples, with a greater number of histology
samples being evaluable for EGFR mutation status.  EGFR mutation pick-up rate in the histology samples was also higher.
EGFR, epidermal growth factor receptor.
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Fig. 3. Tumor cell content of the previously unanalyzed histology and cytology samples (intent-to-treat population).
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Sample type and EGFR mutation status
Previously analyzed (met original sample type or
pathology review criteria)
Previously unanalyzed (did not meet original sample type or
pathology review criteria)  
Previously unanalyzed and per-protocol analysis.
Original pathology review criteria included pre-specified thresholds regarding tumor content, sample quality, and sample quantity.
Objective tumor response (complete response or partial response) was determined by the Response Evaluation Criteria in Solid Tumors, version 1.0. Objective response rates were
calculated as the percentage of the total number of patients analyzed whose tumors had a confirmed overall response of complete response or partial response.
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Fig. 4. Objective response rate for patients treated with geﬁtinib 
atients, including 61 patients described as not previously analyzed
nd who are described here.
Fig. 4 summarizes the ORR in the previously unanalyzed cytol-
gy and histology samples by EGFR mutation status for patients
ith geﬁtinib. The ORR in the EGFR mutation-positive subgroups
y cytology and previously unanalyzed histology samples are
onsistent with the data from the previously determined EGFR
utation-positive subgroups: EGFR mutation-positive on the basis
f cytology ORR 83% (n = 5/6), previously unanalyzed histology sam-
le 74% (n = 20/27) versus 71% in the previous analysis. The ORR in
he EGFR mutation-negative subgroups by cytology and previously
nanalyzed histology samples are higher than those observed in the
reviously determined EGFR mutation-negative subgroups: EGFR
utation-negative on the basis of cytology 16% (n = 2/12), previ-
usly unanalyzed histology sample 25% (n = 4/16) versus 1% in the
revious analysis.
Tumor  size reduction (percentage change from baseline) with
eﬁtinib in the previously unanalyzed cytology and histology sam-
les appears to be consistent with previously analyzed histology
amples, for both EGFR mutation-positive (Fig. 5a and b) and -
egative samples (Fig. 5d and e). The EGFR mutation-positive and
negative tumors from the updated analysis are evenly distributed
hroughout the waterfall plots of the previously analyzed histol-
gy samples (Fig. 5c and f, respectively). Maximum percentage
hange in tumor size from baseline for patients whose tumors
ere of unknown EGFR mutation status is shown in Fig. 6a (includ-
ng previously analyzed samples, and cytology and low tumor
ontent samples), Fig. 6b (previously unanalyzed samples high-
ighting those cytology and low tumor content tumor samples
ubsequently found to be EGFR mutation-positive), and Fig. 6c
previously unanalyzed samples highlighting those cytology and
ow tumor content tumor samples subsequently found to be EGFR
utation-negative).ple type and EGFR mutation status (intent-to-treat population).
4.  Discussion and conclusions
The  results of IPASS clearly demonstrated the differential efﬁ-
cacy of EGFR-TKIs in the EGFR mutation-positive, -negative, and
-unknown subgroups [4,5]. EGFR-TKIs are now recommended for
the treatment of patients with EGFR mutation-positive tumors [15].
As a result of available data, accurate identiﬁcation of patients who
might beneﬁt from EGFR-TKI therapy has become an important step
in the treatment-decision pathway for advanced NSCLC [16].
This  study shows that both histology and cytology samples
used to diagnose NSCLC are suitable for the detection of EGFR
mutations. This study demonstrates that where an EGFR mutation-
positive result is observed, EGFR-TKI efﬁcacy is consistent with that
observed in the sample analysis according to the protocol, albeit
with wider ORR CIs due to sample number. In both the cytology
and previously unanalyzed histology subgroups, a higher response
rate was observed in samples in which no EGFR mutation was
detected compared with the 1% response rate in the previously
analyzed histology samples in which no mutation was  detected.
While the EGFR mutation frequency is as expected in the previ-
ously unanalyzed histology samples, it was  lower than expected
in the cytology samples. Taken together, these two observations
demonstrate that there are likely to be a number of false-negative
results within the EGFR mutation-negative (or EGFR mutation-
not-detected) subgroups in these previously unanalyzed samples,
showing that the EGFR mutation-negative results are less robust
than in the previously analyzed samples of good quality/quantity.
This study therefore demonstrates that while high quality and high
tumor content samples should be obtained and tested where pos-
sible, it is feasible to use low tumor content or cytology samples
if these are the only sample available from the initial diagnosis
of advanced NSCLC. Additionally, feedback from pathologists and
molecular biologists on sample quality would help to minimize
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The horizontal dashed lines at -30% and +20% represent the percentage change required for a response or progression of target lesions, 
respectively, according to Response Evaluation Criteria In Solid Tumors, version 1.0.
Only patients with a baseline and one evaluable post-baseline target lesion assessment are included. Plots do not include
assessment of non-target or new lesions.
EGFR, epidermal growth factor receptor.
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Fig. 5. Waterfall plots for maximum percentage change in tumor size from baseline in patients with EGFR mutation-positive tumors treated with geﬁtinib from (a) previously
analyzed samples, (b) previously unanalyzed samples, and (c) all analyzed samples; and EGFR mutation-negative tumors treated with geﬁtinib from (d) previously analyzed
samples, (e) previously unanalyzed samples, and (f) all analyzed samples.
180 J.C.-H. Yang et al. / Lung Cancer 83 (2014) 174– 181
The horizontal dashed line at 30% shrinkage represents the percentage change required for a response of target lesions according to Response Evaluation 
Criteria In Solid Tumors, version 1.0.
Only patients with a baseline and one evaluable post-baseline target lesion assessment are included. Plots do not include assessment of non-target or new lesions. 
EGFR, epidermal growth factor receptor.
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he costs of repeat testing and optimize the process of obtaining a
uality result that the physician can take into consideration when
aking a treatment decision.
The importance of ensuring that samples are of sufﬁcient qual-
ty/quantity has been conﬁrmed in this study. The EGFR mutation
requency observed in the cytology samples implies that the pre-
peciﬁed tumor content of 100 cells is still relevant within the
linical setting in order to avoid the issue of false-negative results in
his sample type. In contrast, these data suggest that for histology
ample analysis, it may  be possible to reduce the criteria.
Several groups have released recommendations for EGFR
utation testing practices which include guidance on good qual-
ty/quantity samples, but little guidance on how laboratories
hould deal with low tumor content or cytology samples [17–20].
ny samples used for diagnosis of NSCLC (e.g. biopsy, resection,
ytology) should be tested for EGFR mutation status provided the
aboratory performing the analysis is conﬁdent in the result. This
onﬁdence will depend on the method used, laboratory expertise,
nd the quality/quantity of the samples, typically those that contain
ufﬁcient tumor material to obtain an accurate result, regardless
f sample source. Testing of samples judged to be of low quality
r low tumor content should be carried out using sensitive test-
ng methods with or without a technique such as Laser Capture
icrodissection (LCM), to enrich for the tumor cells. This technique
as not attempted in IPASS, because while the technology is avail-
ble in some institutions, it is not widely available and therefore not
ossible for all routine EGFR testing labs to employ. The MolecularAssays  in NSCLC Working Group highlighted that LCM may  be used
to facilitate accurate test results by increasing the ratio of tumor to
normal tissue, which is particularly important for techniques such
as direct sequencing, which requires samples with ≥50–70% tumor
cells for analysis [17]. However, the Working Group also noted that
LCM can be laborious, and is unlikely to be acceptable for routine
clinical sample analysis.
This  analysis of previously unanalyzed samples from IPASS
has shown that NSCLC samples of either low tumor cell con-
tent or cytological origin are suitable for the detection of EGFR
mutation-positive disease. While consideration should be given to
the individual capabilities of diagnostic laboratories, the testing
of these additional samples may  lead to an increase in the num-
ber of successful mutation results, enabling a greater number of
patients to be accurately diagnosed, and receive the most effective
and personalized therapy.
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